Article
Dermatology
S. Staender, C. M. Hammers, A. Vorobyev, E. Schmidt, J. E. Hundt, C. D. Sadik, T. Lange, D. Zillikens, R. J. Ludwig, K. Kridin
Summary: The study found that comorbidity of bullous pemphigoid (BP) with neuropsychiatric diseases is common, with older age and higher proportion of females among patients with neuropsychiatric diseases. Patients with BP and neuropsychiatric conditions also exhibit certain immunological characteristics, such as a higher rate of anti-BP230 positivity.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
Raziyeh Ganji, Zahra Mahboubi-Fooladi, Mohammad Shahidi-Dadras, Zohreh Tehranchinia, Fahimeh Abdollahimajd, Fariba Ghalamkarpour, R. M. Robati, Mehdi Gheisari, Nikoo Mozafari, Sahar Dadkhahfar, Soheila Nasiri
Summary: Evidence suggests that bullous pemphigoid (BP) is associated with multiple neurological disorders. This study aimed to compare brain magnetic resonance imaging (MRI) findings between BP patients and a control group. The results showed that the proportion of grade-3 Fazekas was significantly higher in BP patients compared to controls. In addition, acute infarcts were exclusively observed in BP patients.
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Immunology
Meital Oren-Shabtai, Daniel Mimouni, Adi Nosrati, Lihi Atzmony, Baruch Kaplan, Aviv Barzilai, Sharon Baum
Summary: This study describes the clinical and immunological features of patients with recalcitrant BP treated with immunobiological therapies. The results show that the use of biological treatment can significantly improve the condition of BP patients and has no adverse events.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Carlo Alberto Maronese, Marzia Caproni, Chiara Moltrasio, Giovanni Genovese, Pamela Vezzoli, Paolo Sena, Giulia Previtali, Emanuele Cozzani, Giulia Gasparini, Aurora Parodi, Laura Atzori, Emiliano Antiga, Roberto Maglie, Francesco Moro, Elena Biancamaria Mariotti, Alberto Corra, Sabatino Pallotta, Biagio Didona, Angelo Valerio Marzano, Giovanni Di Zenzo
Summary: Bullous pemphigoid (BP) is an autoimmune disease that COVID-19 vaccines may induce. An Italian study collected data of BP patients associated with COVID-19 vaccines and found that these patients have similar characteristics to idiopathic BP, but with a slight male predominance and reduced humoral response to BP230.
FRONTIERS IN MEDICINE
(2022)
Review
Medicine, General & Internal
Roberto Russo, Niccolo Capurro, Emanuele Cozzani, Aurora Parodi
Summary: Bullous pemphigoid is a common autoimmune blistering disease, and the main treatment options are corticosteroids and immunosuppressant drugs. However, these treatments often come with adverse effects and safety concerns. In recent years, a drug called dupilumab has been used to treat bullous pemphigoid and has shown promising effectiveness and safety.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Immunology
Hiroshi Koga, Kwesi Teye, Arisa Sugawara, Masahiro Tsutsumi, Norito Ishii, Takekuni Nakama
Summary: Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease with a prominent role of T helper 2 (Th2) cells. IL-9 is elevated in the serum and lesions of BP, and could be a biomarker of BP.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Belen de Nicolas-Ruanes, Asuncion Ballester-Martinez, Emilio Garcia-Mouronte, Emilio Berna-Rico, Carlos Azcarraga-Llobet, Montserrat Fernandez-Guarino
Summary: Bullous pemphigoid is the most common autoimmune blistering disease, but its pathogenic mechanisms are still unclear. DPP4i is considered the main trigger for BP, while antineoplastic immunotherapy is also associated with the disease. The relationship with other drugs is less clear.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Ting Wang, Qianwen Shao, Chunmei Xiao, Lianke Liu
Summary: Immunotherapy is effective in treating many cancers but can cause immune-related adverse effects, such as bullous pemphigoid. This article reports a case of bullous pemphigoid caused by PD-1 in a colorectal cancer patient. The patient showed no significant adverse effects after tapering methylprednisone and achieved partial remission for over 8 months.
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
Roberto Maglie, Maria Efenesia Baffa, Francesca Montefusco, Carlo Pipito, Stefano Senatore, Marco Capassoni, Vincenza Maio, Marco Matucci Cerinic, Emiliano Antiga, Serena Guiducci
Summary: This article describes the unusual occurrence of bullous pemphigoid (BP) in a female patient with a concomitant history of generalized morphea and cutaneous and genital lichen sclerosus. The study provides a literature review on cases of BP in patients with localized scleroderma or lichen sclerosus and discusses the immunological mechanisms that may have contributed to the emergence of BP in the patient.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Dermatology
M. S. M. Persson, N. Begum, M. J. Grainge, K. E. Harman, D. Grindlay, S. Gran
Summary: The global incidence of Bullous Pemphigoid is generally low but appears to be increasing over time, with higher rates in Europe and Asia. There is significant heterogeneity in the pooled estimates, indicating that the burden of disease may be underestimated.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Wenjuan Chen, Chen Peng, Jianfeng Zheng, Xiya Lu, Yangfeng Ding, Lina Su
Summary: This case report presents a rare occurrence of bullous pemphigoid (BP) in a woman with severe erythrodermic psoriasis (EP), possibly triggered by beta hemolytic streptococcus infection. This highlights the need for physicians to be attentive to the complicated condition of such patients and further study for better treatment.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Maren M. Limberg, Tobias Weihrauch, Natalie Gray, Nancy Ernst, Karin Hartmann, Ulrike Raap
Summary: Bullous pemphigoid (BP) is an autoimmune blistering skin disease characterized by circulating autoantibodies against BP180 and BP230 proteins. In addition to autoantibodies, effector cells and cell-mediated immunity play important roles in BP pathogenesis. This review aims to summarize the current understanding of eosinophils, basophils, and neutrophils in BP.
Article
Dermatology
Sila Kilic Sayar, Gizem Pinar Sun, Rifkiye Kucukoglu
Summary: This study investigated the demographic and clinical features of a large series of BP patients in Turkey, finding a higher prevalence of pre-existing neurological and systemic disorders among the patients. The study also revealed a higher occurrence of pre-existing neurological disorders, stroke, and malignancies among BP patients compared to controls. Additionally, BP patients with neurological disorders had significantly higher serum titers of anti-BP180 and 230 IgG antibodies at the time of diagnosis.
DERMATOLOGIC THERAPY
(2021)
Article
Immunology
Franziska Schauer, David Rafei-Shamsabadi, Shoko Mai, Yosuke Mai, Kentaro Izumi, Frank Meiss, Dimitra Kiritsi
Summary: Immune checkpoint inhibitors (ICI) can induce T-cell-mediated antitumour responses and have been approved for several tumour entities. However, they can also lead to autoimmune disorders, including bullous pemphigoid (BP). In this study, we describe a cohort of eight patients who developed BP under or shortly after ICI treatment. Half of them had a severe subtype and the median onset of ICI-BP was 10 months after ICI initiation. The disease may require treatment with rituximab for remission even after ICI discontinuation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Dermatology
M. S. M. Persson, K. E. Harman, Y. Vinogradova, S. M. Langan, J. Hippisley-Cox, K. S. Thomas, S. Gran
Summary: The study found an increase in the incidence rate of BP in England, especially among elderly men. The burden of disease in the elderly population is substantial, and mortality is significantly higher in the first 2 years after a BP diagnosis.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Letter
Dermatology
Eleni Papakonstantinou, Vivien Schacht, Alexander Kapp, Ulrike Raap
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2018)
Article
Dermatology
G. Bindke, K. Schorling, D. Wieczorek, A. Kapp, B. Wedi
Article
Medicine, General & Internal
Mark S. Dykewicz, Jason K. Lam
MEDICAL CLINICS OF NORTH AMERICA
(2020)
Letter
Dermatology
S. Traidl, Y. Angela, B. Wedi, A. Kapp, T. Werfel, V. Schacht
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Review
Medicine, General & Internal
Aylin Ruppenstein, Maren M. Limberg, Karin Loser, Andreas E. Kremer, Bernhard Homey, Ulrike Raap
Summary: Pruritus is a common and challenging symptom with diverse underlying causes, affecting quality of life for patients with chronic pruritus. The complex physiology of pruritus involves interactions among skin components and immune cells, which play a significant role in the transmission of itch signals. Targeting neuro-immune interactions and specific receptors related to pruritus may provide new insights for treatment options.
FRONTIERS IN MEDICINE
(2021)
Letter
Dermatology
S. Traidl, Y. Angela, A. Stender, A. Kulberg, M. Tronnier, N. K. Prenzler, M. P. Wattjes, A. Kapp, M. Stangel, V. Schacht, T. Werfel
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Review
Dermatology
N. Gray, M. M. Limberg, A. U. Braeuer, U. Raap
Summary: S1P is a pleiotropic sphingolipid signaling molecule that influences cell fate and immune cell trafficking. Evidence suggests that dysfunction and imbalance of the S1P-axis may contribute to inflammatory skin diseases, while studies on modulators targeting the S1P pathway show promising therapeutic potential.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Natalie Gray, Maren M. Limberg, Daniela Wiebe, Tobias Weihrauch, Anna Langner, Nicola Brandt, Anja U. Braeuer, Ulrike Raap
Summary: The interaction between S1P and basophils may play an important role in the pathophysiology of atopic diseases. S1P affects the function of basophils and basophils from atopic patients have reduced chemotactic activity in response to S1P.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Tobias Weihrauch, Maren M. Limberg, Natalie Gray, Martin Schmelz, Ulrike Raap
Summary: Allergic diseases can cause various symptoms such as itching, coughing, sneezing, and watery eyes, leading to severe physiological and psychological impairments. The mechanisms of these conditions are still not fully understood, but recent studies have shown the high relevance of neurotrophins in allergic inflammation. Neurotrophins induce cytokine release, facilitate interactions between immune cells and neurons, and show different expression levels in health and disease. In this review, the role of neurotrophins in atopic disorders like atopic dermatitis, allergic asthma, and allergic rhinitis is discussed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Ulrike Raap, Maren M. M. Limberg, Khalaf Kridin, Ralf J. J. Ludwig
Summary: Autoimmune bullous skin diseases (AIBDs), such as bullous pemphigoid (BP) and pemphigus, are characterized by autoantibodies targeting structural proteins. Pruritus is common in patients with BP and pemphigus, and can be the sole symptom in some cases. The temporal relationship between pruritus and AIBDs is unclear, and the presence of pruritus in other AIBDs is also unknown.
Article
Allergy
Maren M. Limberg, Daniela Wiebe, Natalie Gray, Tobias Weihrauch, Anja U. Braeuer, Andreas E. Kremer, Bernhard Homey, Ulrike Raap
Meeting Abstract
Dermatology
S. Traidl, D. Wieczorek, A. Kapp, B. Wedi
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2021)
Meeting Abstract
Dermatology
H. Asper, A. Kapp, M. Schefzyk, T. Werfel
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2019)
